In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...
GSK stock declined 3% despite beating Q1 earnings estimates. Analysts note legal provisions contributed half the beat.
GSK posted above-forecast first-quarter profits on Wednesday, boosted by robust demand for its specialist HIV and oncology ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
GSK plc (NYSE:GSK) is one of the 7 Most Profitable Value Stocks to Buy Right Now. GSK plc (NYSE:GSK) is one of the most profitable value stocks to buy right now. On March 13, GSK plc announced that ...
Zacks Investment Research on MSN
GSK Q1 earnings beat estimates, specialty medicines drive sales growth
GSK plc GSK reported first-quarter 2026 core earnings of $1.26 per American depositary share (ADS), which beat the Zacks ...
Juxtapid (lomitapide) Microsomal triglyceride transfer protein inhibitor Treatment of pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia. Juxtapid Approved for ...
Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory studies prevented the virus from developing drug resistance—a persistent ...
RSV jabs are being made free for older Australians. The respiratory syncytial virus vaccinations will be available without charge to people 75 and older to ensure protection from the common and ...
Hosted on MSN
GSK wins FDA label expansion for RSV vaccine, Arexvy
GSK (GSK) announced on Friday that the U.S. Food and Drug Administration (FDA) has approved a label expansion for its Arexvy vaccine against the Respiratory Syncytial Virus (RSV) to allow its use for ...
Showcase your company news with guaranteed exposure both in print and online Gather your employees for an afternoon of fun as we honor the Denver metro area… A panel of dynamic developers and leaders ...
Alert FDA Approves Deucravacitinib as First TYK2 Inhibitor for PsA In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results